Figure 2 | Scientific Reports

Figure 2

From: Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR−/− mice

Figure 2

Fenretinide inhibits hepatic triglyceride accumulation and development of steatosis. (A) Hepatic triglyceride levels in LDLR−/− mice. (B) Representative H&E staining of hepatic tissues. Scale bar is 20 µm. (C–F) Gene expression in liver tissue (n = 8 per group). Data are represented as mean + S.E.M. and analysed by one-way ANOVA followed by Bonferroni multiple comparison t-tests where *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001 (control compared to HFD) or #p ≤ 0.05 and ##p ≤ 0.01 (HFD compared to FEN-HFD).

Back to article page